DeepDRP: Dose-response predictions of drug pairs using deep learning based on data-driven feature representation and dose-response curve characteristics

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not specified in abstract

• Primary Outcome: Superior prediction performance compared to other computational approaches

• Nnt Or Sensitivity: Prediction accuracy metrics not specified

• Confidence Interval: Not reported

Clinical Application

Requires computational infrastructure and integration with clinical decision support systems Could support TGA drug combination approvals and PBS cost-effectiveness assessments if clinically validated. Relevant to Cancer Australia treatment guidelines development. Potentially applicable to oncology patients receiving combination chemotherapy, pending clinical validation

Abstract

Combination therapies have become a cornerstone of modern medicine, offering improved treatment outcomes and reduced side effects compared to monotherapies. However, the efficacy and safety of drug combinations depend heavily on the specific doses of each component, making the optimization of dosing regimens a crucial yet challenging task. Despite the importance of dose optimization, few computational methods address this challenge. Here, we propose DeepDRP, a novel approach that integrates two complementary models: the global model, which is trained using all available combinations, and the local model, which utilizes only samples with similar information to queries. The DeepDRP architecture comprises three main modules: the first module has three embedding networks to extract features from drugs, doses, and cell lines, and then predicts synergy using the fused knowledge. The second module constructs a graph using the input query and the set of similar retrieved training samples fed into a semi-supervised graph convolutional network to predict the synergy value. Finally, these two models are aggregated to have the final predicted value. To evaluate the proposed approach, it is applied to the NCI-ALMANAC dataset and O'Neil dataset. The obtained results denote that the proposed method achieves superior performance with respect to the other approaches.

References

1. 1.Moragheb, M., Dehghan, A., Razzaghi, P., & Gharaghani, S. (2026). DeepDRP: Dose-response predictions of drug pairs using deep learning based on data-driven feature representation and dose-response curve characteristics. PLoS One. https://doi.org/10.1371/journal.pone.0348908